Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Palovarotene - Clementia Pharmaceuticals

X
Drug Profile

Palovarotene - Clementia Pharmaceuticals

Alternative Names: Clm-001; IPN-60120; R-667; RAR-gamma; RG-667; RO-3300074; Sohonos

Latest Information Update: 13 Feb 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Roche
  • Developer Clementia Pharmaceuticals; Ipsen; Roche
  • Class Benzoic acids; Eye disorder therapies; Naphthalenes; Pyrazoles; Small molecules
  • Mechanism of Action Retinoic acid receptor gamma agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Fibrodysplasia ossificans progressiva
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Fibrodysplasia ossificans progressiva
  • Discontinued Bone disorders; Dry eyes; Emphysema

Most Recent Events

  • 08 Feb 2024 Launched for Fibrodysplasia ossificans progressiva (In adolescents, In children, In adults) in USA (PO), before February 2024
  • 28 Nov 2023 Registered for Fibrodysplasia ossificans progressiva (In adolescents, In children, In adults) in Australia (PO)
  • 26 Oct 2023 Ipsen announces intention to launch Palovarotene in USA
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top